Myelodysplastic syndromes Journal Article

  


Authors: Greenberg, P. L.; Attar, E.; Bennett, J. M.; Bloomfield, C. D.; De Castro, C. M.; Deeg, H. J.; Foran, J. M.; Gaensler, K.; Garcia-Manero, G.; Gore, S. D.; Head, D.; Komrokji, R.; Maness, L. J.; Millenson, M.; Nimer, S. D.; O'Donnell, M. R.; Schroeder, M. A.; Shami, P. J.; Stone, R. M.; Thompson, J. E.; Westervelt, P.
Article Title: Myelodysplastic syndromes
Abstract: These suggested practice guidelines are based on extensive evaluation of the reviewed risk-based data and indicate useful current approaches for managing patients with MDS. Four drugs have recently been approved by the FDA for treating specific subtypes of MDS: lenalidomide for MDS patients with del(5q) cytogenetic abnormalities; azacytidine and decitabine for treating patients with higher-risk or nonresponsive MDS; and deferasirox for iron chelation of iron overloaded patients with MDS. However, because a substantial proportion of patient subsets with MDS lack effective treatment for their cytopenias or for altering disease natural history, clinical trials with these and other novel therapeutic agents along with supportive care remain the hallmark of management for this disease. The role of thrombopoietic cytokines for management of thrombocytopenia in MDS needs further evaluation. In addition, further determination of the effects of these therapeutic interventions on the patient's quality of life is important.116,119,120,128,129 Progress toward improving management of MDS has occurred over the past few years, and more advances are anticipated using these guidelines as a framework for coordination of comparative clinical trials. © JNCCN-Journal of the National Comprehensive Cancer Network.
Keywords: chronic myelomonocytic leukemia; fludarabine; lenalidomide; thalidomide; histopathology; neutropenia; review; disease classification; clinical trials as topic; chemotherapy; treatment; cytarabine; topotecan; flow cytometry; imatinib; quality of life; anemia; thrombocytopenia; nccn clinical practice guidelines; practice guideline; hematopoietic stem cell transplantation; high risk patient; standard; myelodysplastic syndrome; gene rearrangement; bone marrow biopsy; vitamin d; scoring system; psychosocial care; 5 aza 2' deoxycytidine; tumor necrosis factor receptor; blood cell count; idarubicin; erythrocyte transfusion; genetic screening; granulocyte colony stimulating factor; cytopenia; recombinant erythropoietin; cyclosporin; deferoxamine; azacitidine; immunosuppressive agent; myelodysplastic syndromes; blood smear; thymocyte antibody; thrombocyte transfusion; ferritin blood level; iron chelation; nccn guidelines; cytopenias; refractory anemia; clinical trial (topic); deferasirox; novel erythropoiesis stimulating protein; iron overload; aminocaproic acid; myelomonocytic leukemia; refractory anemia with excess blasts; refractory anemia with ringed sideroblasts; deferiprone; refractory anemia with excess blasts in transformation; antifibrinolytic agent; international prognostic scoring system
Journal Title: Journal of the National Comprehensive Cancer Network
Volume: 9
Issue: 1
ISSN: 1540-1405
Publisher: Harborside Press  
Date Published: 2011-01-01
Start Page: 30
End Page: 56
Language: English
PROVIDER: scopus
DOI/URL:

http://www.scopus.com/inward/record.url?eid=2-s2.0-78951487923&partnerID=40&md5=37dbbe52d88d86fe0041a0414897723f
Notes: --- - "Export Date: 4 March 2011" - "Source: Scopus"